09.23.26 -- Why Specialty Samples And Protocol Choices Are Putting Trials At Risk

Biomarkers and other specialty lab samples are among the most fragile parts of clinical trial execution, but what makes them so vulnerable to mishandling, and what are the effects?

This presentation explores practical pharmacy considerations in early-phase clinical trials, offering real-world insights from experienced clinical research pharmacists.

Learn how protocol choices like AI, adaptive designs, and decentralized methods impact IRB review, participant protections, consent, and key regulatory requirements in clinical research.

Successful RTSM delivery depends on more than software alone; it also requires experienced teams supporting the process.

We know that functional outsourcing is vital to clinical development today. This is why we build relationships and communicate with you to develop effective solutions.

 Discover how new approaches can improve patient assessment, enable precision medicine, and help address key challenges in developing effective obesity therapies.

Explore how clinical trial sponsors can benefit from the growing use of electronic source (eSource) technology at research sites.

Having problems interpreting ICH guidelines or deciding what to do next? Sophia McLeod offers some advice and resources, and then she also explains why she thinks it’s good that we’re living in this “show-your-work” kind of era.